Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life-Reference-Cited by-同舟云学术

Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life

Published:2018-10-30 Issue:11-12 Volume:48 Page:1174-1185
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Paschos Paschalis¹²^ORCID,Katsoula Anastasia¹^ORCID,Salanti Georgia³,Giouleme Olga⁴,Athanasiadou Eleni¹,Tsapas Apostolos¹⁵

Affiliation:

1. Clinical Research and Evidence-Based Medicine Unit; Second Medical Department; Aristotle University of Thessaloniki; Thessaloniki Greece

2. First Department of Internal Medicine; “Papageorgiou” Hospital; Thessaloniki Greece

3. Institute of Social and Preventive Medicine & Clinical Trials Unit; University of Bern; Bern Switzerland

4. Second Propaedeutic Department of Internal Medicine; Aristotle University of Thessaloniki; Thessaloniki Greece

5. Harris Manchester College; University of Oxford; Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15005/fullpdf

Reference43 articles.

1. Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders;Magro;J Crohns Colitis,2017

2. Food and Drug Administration Ulcerative Colitis: Clinical Trial Endpoints Guidance for Industry 2016 https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM515143.pdf

3. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol,2015

4. The impact of biological interventions for ulcerative colitis on health-related quality of life;LeBlanc;Cochrane Database Syst Rev,2015

5. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool;Salanti;Res Synth Methods,2012

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment;Journal of Clinical Medicine;2024-01-05

2. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study;Digestive and Liver Disease;2024-01

3. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis;Journal of Clinical Medicine;2023-07-30

4. Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?;Journal of Personalized Medicine;2023-06-02

5. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries;BMC Gastroenterology;2023-01-19